Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis

Marc A. Sintek, Christopher T. Sparrow, Ted R Mikuls, Kathryn J. Lindley, Richard G. Bach, Howard I. Kurz, Eric Novak, Jasvindar Singh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To investigate repeat revascularisation outcomes in patients with rheumatoid arthritis(RA) after percutaneous coronary intervention (PCI). Methods We performed a single-centre, retrospective matched cohort study of patients with RA matched to non-RA patients post PCI. Primary endpoints were time to target lesion revascularisation (TLR) and target vessel revascularisation (TVR) analysed by Cox proportional hazard shared frailty models. Results A total of 228 lesions (143 patients) were identified in the RA cohort and matched to 677 control lesions (541 patients). TLR occurred in 33% (n=75) of RA lesions versus 25% (n=166) of control lesions (adjusted HR 1.3; 95% CI 0.97 to 1.8). TVR occurred in 39% (n=89) of RA lesions versus 31% (n=213) of control lesions (adjusted HR 1.15; 95% CI 0.82 to 1.6). There was a significant hazard for TLR (adjusted HR 1.48; 95% CI 1.03 to 2.13) and TVR (adjusted HR 1.55; 95% CI 1.12 to 2.14) when excluding lesions with revascularisation events or follow-up less than 1 year. When stratified by treatment with methotrexate or tumour necrosis factor (TNF) α inhibitors or both at discharge, lesions from patients with RA treated with these agents had similar TVR and TLR as control lesions, whereas lesions from patients with RA not treated with these agents had significantly more TLR and TVR (TLR adjusted HR 1.48; 95% CI 1.08 to 2.03; TVR adjusted HR 1.38; 95% CI 1.04 to 1.84). Conclusions RA predisposes to repeat revascularisation, specifically in patients followed after the 1-year landmark. In the absence of RA treatments including methotrexate and/or TNFα inhibitors, RA is associated with a 50% increased relative risk of repeat revascularisation following PCI. These findings emphasise the adverse effects of chronic inflammation on the durability of PCI and provide further support for aggressive anti-inflammatory treatment in patients with RA.

Original languageEnglish (US)
Pages (from-to)363-369
Number of pages7
JournalHeart
Volume102
Issue number5
DOIs
StatePublished - Mar 2016

Fingerprint

Percutaneous Coronary Intervention
Rheumatoid Arthritis
Methotrexate
Tumor Necrosis Factor-alpha
Patient Discharge
Arthritis
Cohort Studies
Anti-Inflammatory Agents
Therapeutics
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis. / Sintek, Marc A.; Sparrow, Christopher T.; Mikuls, Ted R; Lindley, Kathryn J.; Bach, Richard G.; Kurz, Howard I.; Novak, Eric; Singh, Jasvindar.

In: Heart, Vol. 102, No. 5, 03.2016, p. 363-369.

Research output: Contribution to journalArticle

Sintek, MA, Sparrow, CT, Mikuls, TR, Lindley, KJ, Bach, RG, Kurz, HI, Novak, E & Singh, J 2016, 'Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis', Heart, vol. 102, no. 5, pp. 363-369. https://doi.org/10.1136/heartjnl-2015-308634
Sintek, Marc A. ; Sparrow, Christopher T. ; Mikuls, Ted R ; Lindley, Kathryn J. ; Bach, Richard G. ; Kurz, Howard I. ; Novak, Eric ; Singh, Jasvindar. / Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis. In: Heart. 2016 ; Vol. 102, No. 5. pp. 363-369.
@article{771d95c3b4c14cdfbc196af852a1b640,
title = "Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis",
abstract = "Objective To investigate repeat revascularisation outcomes in patients with rheumatoid arthritis(RA) after percutaneous coronary intervention (PCI). Methods We performed a single-centre, retrospective matched cohort study of patients with RA matched to non-RA patients post PCI. Primary endpoints were time to target lesion revascularisation (TLR) and target vessel revascularisation (TVR) analysed by Cox proportional hazard shared frailty models. Results A total of 228 lesions (143 patients) were identified in the RA cohort and matched to 677 control lesions (541 patients). TLR occurred in 33{\%} (n=75) of RA lesions versus 25{\%} (n=166) of control lesions (adjusted HR 1.3; 95{\%} CI 0.97 to 1.8). TVR occurred in 39{\%} (n=89) of RA lesions versus 31{\%} (n=213) of control lesions (adjusted HR 1.15; 95{\%} CI 0.82 to 1.6). There was a significant hazard for TLR (adjusted HR 1.48; 95{\%} CI 1.03 to 2.13) and TVR (adjusted HR 1.55; 95{\%} CI 1.12 to 2.14) when excluding lesions with revascularisation events or follow-up less than 1 year. When stratified by treatment with methotrexate or tumour necrosis factor (TNF) α inhibitors or both at discharge, lesions from patients with RA treated with these agents had similar TVR and TLR as control lesions, whereas lesions from patients with RA not treated with these agents had significantly more TLR and TVR (TLR adjusted HR 1.48; 95{\%} CI 1.08 to 2.03; TVR adjusted HR 1.38; 95{\%} CI 1.04 to 1.84). Conclusions RA predisposes to repeat revascularisation, specifically in patients followed after the 1-year landmark. In the absence of RA treatments including methotrexate and/or TNFα inhibitors, RA is associated with a 50{\%} increased relative risk of repeat revascularisation following PCI. These findings emphasise the adverse effects of chronic inflammation on the durability of PCI and provide further support for aggressive anti-inflammatory treatment in patients with RA.",
author = "Sintek, {Marc A.} and Sparrow, {Christopher T.} and Mikuls, {Ted R} and Lindley, {Kathryn J.} and Bach, {Richard G.} and Kurz, {Howard I.} and Eric Novak and Jasvindar Singh",
year = "2016",
month = "3",
doi = "10.1136/heartjnl-2015-308634",
language = "English (US)",
volume = "102",
pages = "363--369",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis

AU - Sintek, Marc A.

AU - Sparrow, Christopher T.

AU - Mikuls, Ted R

AU - Lindley, Kathryn J.

AU - Bach, Richard G.

AU - Kurz, Howard I.

AU - Novak, Eric

AU - Singh, Jasvindar

PY - 2016/3

Y1 - 2016/3

N2 - Objective To investigate repeat revascularisation outcomes in patients with rheumatoid arthritis(RA) after percutaneous coronary intervention (PCI). Methods We performed a single-centre, retrospective matched cohort study of patients with RA matched to non-RA patients post PCI. Primary endpoints were time to target lesion revascularisation (TLR) and target vessel revascularisation (TVR) analysed by Cox proportional hazard shared frailty models. Results A total of 228 lesions (143 patients) were identified in the RA cohort and matched to 677 control lesions (541 patients). TLR occurred in 33% (n=75) of RA lesions versus 25% (n=166) of control lesions (adjusted HR 1.3; 95% CI 0.97 to 1.8). TVR occurred in 39% (n=89) of RA lesions versus 31% (n=213) of control lesions (adjusted HR 1.15; 95% CI 0.82 to 1.6). There was a significant hazard for TLR (adjusted HR 1.48; 95% CI 1.03 to 2.13) and TVR (adjusted HR 1.55; 95% CI 1.12 to 2.14) when excluding lesions with revascularisation events or follow-up less than 1 year. When stratified by treatment with methotrexate or tumour necrosis factor (TNF) α inhibitors or both at discharge, lesions from patients with RA treated with these agents had similar TVR and TLR as control lesions, whereas lesions from patients with RA not treated with these agents had significantly more TLR and TVR (TLR adjusted HR 1.48; 95% CI 1.08 to 2.03; TVR adjusted HR 1.38; 95% CI 1.04 to 1.84). Conclusions RA predisposes to repeat revascularisation, specifically in patients followed after the 1-year landmark. In the absence of RA treatments including methotrexate and/or TNFα inhibitors, RA is associated with a 50% increased relative risk of repeat revascularisation following PCI. These findings emphasise the adverse effects of chronic inflammation on the durability of PCI and provide further support for aggressive anti-inflammatory treatment in patients with RA.

AB - Objective To investigate repeat revascularisation outcomes in patients with rheumatoid arthritis(RA) after percutaneous coronary intervention (PCI). Methods We performed a single-centre, retrospective matched cohort study of patients with RA matched to non-RA patients post PCI. Primary endpoints were time to target lesion revascularisation (TLR) and target vessel revascularisation (TVR) analysed by Cox proportional hazard shared frailty models. Results A total of 228 lesions (143 patients) were identified in the RA cohort and matched to 677 control lesions (541 patients). TLR occurred in 33% (n=75) of RA lesions versus 25% (n=166) of control lesions (adjusted HR 1.3; 95% CI 0.97 to 1.8). TVR occurred in 39% (n=89) of RA lesions versus 31% (n=213) of control lesions (adjusted HR 1.15; 95% CI 0.82 to 1.6). There was a significant hazard for TLR (adjusted HR 1.48; 95% CI 1.03 to 2.13) and TVR (adjusted HR 1.55; 95% CI 1.12 to 2.14) when excluding lesions with revascularisation events or follow-up less than 1 year. When stratified by treatment with methotrexate or tumour necrosis factor (TNF) α inhibitors or both at discharge, lesions from patients with RA treated with these agents had similar TVR and TLR as control lesions, whereas lesions from patients with RA not treated with these agents had significantly more TLR and TVR (TLR adjusted HR 1.48; 95% CI 1.08 to 2.03; TVR adjusted HR 1.38; 95% CI 1.04 to 1.84). Conclusions RA predisposes to repeat revascularisation, specifically in patients followed after the 1-year landmark. In the absence of RA treatments including methotrexate and/or TNFα inhibitors, RA is associated with a 50% increased relative risk of repeat revascularisation following PCI. These findings emphasise the adverse effects of chronic inflammation on the durability of PCI and provide further support for aggressive anti-inflammatory treatment in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=84964300016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964300016&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2015-308634

DO - 10.1136/heartjnl-2015-308634

M3 - Article

C2 - 26719360

AN - SCOPUS:84964300016

VL - 102

SP - 363

EP - 369

JO - Heart

JF - Heart

SN - 1355-6037

IS - 5

ER -